Literature DB >> 12414975

Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.

Javier Martinez-Picado1, Simon D W Frost, Nuria Izquierdo, K Morales-Lopetegi, Silvia Marfil, Teresa Puig, Cecilia Cabrera, Bonaventura Clotet, Lidia Ruiz.   

Abstract

We analyzed the evolution of the human immunodeficiency virus type 1 (HIV-1) env gene in 12 chronically infected individuals who underwent structured treatment interruptions (STIs). Analyses of length variation and of clonal sequences demonstrated highly unpredictable evolution, which may limit the strengthening of HIV-specific immune responses by STIs because of the variability in exposure to viral antigens.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12414975      PMCID： PMC136865          DOI： 10.1128/jvi.76.23.12344-12348.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

Authors:  F García; M Plana; C Vidal; A Cruceta; W A O'Brien; G Pantaleo; T Pumarola; T Gallart; J M Miró; J M Gatell
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models.

Authors:  Z Yang; R Nielsen
Journal:  Mol Biol Evol       Date:  2000-01       Impact factor: 16.240

3.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

4.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

5.  Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.

Authors:  H Imamichi; K A Crandall; V Natarajan; M K Jiang; R L Dewar; S Berg; A Gaddam; M Bosche; J A Metcalf; R T Davey ; H C Lane
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

6.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Authors:  L Ruiz; G Carcelain; J Martínez-Picado; S Frost; S Marfil; R Paredes; J Romeu; E Ferrer; K Morales-Lopetegi; B Autran; B Clotet
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

7.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Authors:  E Papasavvas; G M Ortiz; R Gross; J Sun; E C Moore; J J Heymann; M Moonis; J K Sandberg; L A Drohan; B Gallagher; J Shull; D F Nixon; J R Kostman; L J Montaner
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

8.  Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.

Authors:  S Philpott; B Weiser; K Anastos; C M Kitchen; E Robison; W A Meyer; H S Sacks; U Mathur-Wagh; C Brunner; H Burger
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

9.  Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

Authors:  L Zhang; C Chung; B S Hu; T He; Y Guo; A J Kim; E Skulsky; X Jin; A Hurley; B Ramratnam; M Markowitz; D D Ho
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

10.  Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Authors:  M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307
View more
  13 in total

1.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

2.  Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Authors:  Marta E Bull; Jennifer L McKernan; Sheila Styrchak; Kelli Kraft; Jane Hitti; Susan E Cohn; Kenneth Tapia; Wenjie Deng; Sarah Holte; James I Mullins; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-30       Impact factor: 2.205

3.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

4.  Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.

Authors:  Javier Martinez-Picado; Terri Wrin; Simon D W Frost; Bonaventura Clotet; Lidia Ruiz; Andrew J Leigh Brown; Christos J Petropoulos; Neil T Parkin
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Authors:  Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

6.  Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.

Authors:  Emmanouil Papasavvas; Andrea Foulkes; Xiaohong Li; Jay R Kostman; Karam C Mounzer; Luis J Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

7.  Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.

Authors:  Mark Sharkey; Dunja Z Babic; Thomas Greenough; Roy Gulick; Daniel R Kuritzkes; Mario Stevenson
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

8.  Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.

Authors:  Weijun Zhu; Yanmei Jiao; Rongyue Lei; Wei Hua; Rui Wang; Yunxia Ji; Zhiying Liu; Feili Wei; Tong Zhang; Xuanlin Shi; Hao Wu; Linqi Zhang
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

9.  Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

Authors:  Maria J Buzón; Francisco M Codoñer; Simon D W Frost; Christian Pou; Maria C Puertas; Marta Massanella; Judith Dalmau; Josep M Llibre; Mario Stevenson; Julià Blanco; Bonaventura Clotet; Roger Paredes; Javier Martinez-Picado
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

10.  Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.

Authors:  Amisha Malhotra; Sunanda Gaur; Patricia Whitley-Williams; Caitlin Loomis; Anna Petrova
Journal:  AIDS Res Ther       Date:  2007-07-09       Impact factor: 2.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.